Abstract | BACKGROUND: METHODS: We determined flow-mediated vasodilatation (FMD) as a measure of endothelial-dependent vasodilatory capacity, exhaled CO, bilirubin, and guanosine 3',5'-cyclic monophosphate (cGMP) in 63 subjects with OSA (normotensive 27, hypertensive 36) and in 32 subjects without OSA (normotensive 19, hypertensive 13). RESULTS: Hypertensive OSA demonstrated marked impairment in FMD (8.0 ± 0.5% vasodilatation) compared to 10.5 ± 0.8% in hypertensives non-OSA (P < 0.01) and 13.5 ± 0.5% in normotensive OSA (P < 0.001) and 16.1 ± 1.1% in normotensive non-OSA (P < 0.0001). HO was upregulated and plasma nitric oxide (NO) was significantly increased in hypertensive OSA compared to normotensive OSA and hypertensive non-OSA. Conversely, serum cGMP was markedly decreased in hypertensive OSA (12.9 ± 1.8 pmol/ml vs. 20.6 ± 3.7 in normotensive OSA, P = 0.032). There was an inverse relationship between FMD and CO and bilirubin concentrations (r = 0.43, P = 0.0001 and r = 0.28, P = 0.01, respectively). CONCLUSIONS: These data show that increased CO in the setting of elevated NO concentrations is associated with decreased cGMP, impaired FMD, and hypertension in patient with OSA.
|
Authors | Behrouz Jafari, Vahid Mohsenin |
Journal | American journal of hypertension
(Am J Hypertens)
Vol. 25
Issue 8
Pg. 854-61
(Aug 2012)
ISSN: 1941-7225 [Electronic] United States |
PMID | 22647785
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carbon Monoxide
- Heme Oxygenase (Decyclizing)
- Cyclic GMP
- Bilirubin
|
Topics |
- Bilirubin
(blood)
- Carbon Monoxide
(metabolism)
- Cyclic GMP
(blood)
- Enzyme Activation
- Female
- Heme Oxygenase (Decyclizing)
(metabolism)
- Humans
- Hypertension
(complications, physiopathology)
- Male
- Middle Aged
- Sleep Apnea, Obstructive
(complications, physiopathology)
- Vasodilation
|